Macquarie Group Ltd. decreased its position in Express Scripts Holding Co (NASDAQ:ESRX) by 3.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,221,892 shares of the company’s stock after selling 302,851 shares during the period. Express Scripts accounts for 1.2% of Macquarie Group Ltd.’s portfolio, making the stock its 14th largest position. Macquarie Group Ltd. owned 1.64% of Express Scripts worth $712,021,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Highland Capital Management LP bought a new position in Express Scripts during the second quarter worth about $703,000. Wolverine Asset Management LLC raised its position in shares of Express Scripts by 110.8% during the second quarter. Wolverine Asset Management LLC now owns 39,281 shares of the company’s stock worth $3,032,000 after purchasing an additional 20,646 shares during the period. Voya Investment Management LLC raised its position in shares of Express Scripts by 5.1% during the second quarter. Voya Investment Management LLC now owns 512,937 shares of the company’s stock worth $39,604,000 after purchasing an additional 24,684 shares during the period. BTG Pactual Global Asset Management Ltd raised its position in shares of Express Scripts by 200.0% during the second quarter. BTG Pactual Global Asset Management Ltd now owns 60,000 shares of the company’s stock worth $4,633,000 after purchasing an additional 40,000 shares during the period. Finally, First Republic Investment Management Inc. raised its position in shares of Express Scripts by 7.5% during the second quarter. First Republic Investment Management Inc. now owns 43,220 shares of the company’s stock worth $3,337,000 after purchasing an additional 3,023 shares during the period. Institutional investors and hedge funds own 84.73% of the company’s stock.
A number of research firms have recently commented on ESRX. Robert W. Baird lowered Express Scripts from an “outperform” rating to a “neutral” rating and set a $81.00 price target on the stock. in a research report on Friday, July 20th. BidaskClub raised Express Scripts from a “hold” rating to a “buy” rating in a research report on Wednesday, June 13th. William Blair raised Express Scripts from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 1st. Zacks Investment Research lowered Express Scripts from a “hold” rating to a “sell” rating in a research report on Monday, July 23rd. Finally, Royal Bank of Canada raised their price target on Express Scripts to $94.00 and gave the stock an “outperform” rating in a research report on Monday, August 27th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $85.58.
In other Express Scripts news, insider Christine Houston sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 13th. The stock was sold at an average price of $82.28, for a total transaction of $822,800.00. Following the transaction, the insider now owns 108,010 shares of the company’s stock, valued at approximately $8,887,062.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.79% of the stock is currently owned by company insiders.
Shares of Express Scripts stock opened at $90.90 on Monday. Express Scripts Holding Co has a 52-week low of $55.80 and a 52-week high of $91.03. The company has a market capitalization of $51.04 billion, a P/E ratio of 12.80, a PEG ratio of 1.14 and a beta of 0.99. The company has a current ratio of 0.71, a quick ratio of 0.59 and a debt-to-equity ratio of 0.69.
Express Scripts (NASDAQ:ESRX) last announced its earnings results on Wednesday, August 1st. The company reported $2.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.20 by $0.02. Express Scripts had a return on equity of 25.49% and a net margin of 4.65%. The business had revenue of $25.64 billion for the quarter, compared to analyst estimates of $25.43 billion. During the same quarter last year, the firm earned $1.73 EPS. Express Scripts’s revenue for the quarter was up 1.2% compared to the same quarter last year. research analysts forecast that Express Scripts Holding Co will post 9.07 earnings per share for the current year.
Express Scripts Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Featured Story: NASDAQ
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.